1-8 of 8
David McDermott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma

Thomas Denize, Yue Hou, Jean-Christophe Pignon, Emily Walton, Destiny J. West, Gordon J. Freeman, David A. Braun, Catherine J. Wu, Saurabh Gupta, Robert J. Motzer, Michael B. Atkins, David McDermott, Toni K. Choueiri, Sachet A. Shukla, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4045–4055.
https://doi.org/10.1158/1078-0432.CCR-22-0923
Published: 15 September 2022
View articletitled, Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Open the PDF for Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D. Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F. Stephen Hodi, Myung-Ju Ahn, Leisha A. Emens, Fabrice Barlesi, Omid Hamid, Emiliano Calvo, David McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Tsuhako, Kari Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3220–3228.
https://doi.org/10.1158/1078-0432.CCR-18-2740
Published: 03 June 2019
View articletitled, Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Open the PDF for Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors in another window
Journal Articles

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Neil H. Segal, Theodore F. Logan, F. Stephen Hodi, David McDermott, Ignacio Melero, Omid Hamid, Henrik Schmidt, Caroline Robert, Vanna Chiarion-Sileni, Paolo A. Ascierto, Michele Maio, Walter J. Urba, Tara C. Gangadhar, Satyendra Suryawanshi, Jaclyn Neely, Maria Jure-Kunkel, Suba Krishnan, Holbrook Kohrt, Mario Sznol, Ronald Levy
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1929–1936.
https://doi.org/10.1158/1078-0432.CCR-16-1272
Published: 13 April 2017
View articletitled, Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Open the PDF for Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody in another window
Includes: Supplementary data
Journal Articles

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

John Fruehauf, Jose Lutzky, David McDermott, Charles K. Brown, Jean-Baptiste Meric, Brad Rosbrook, David R. Shalinsky, Katherine F. Liau, Andreas G. Niethammer, Sinil Kim, Olivier Rixe
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7462–7469.
https://doi.org/10.1158/1078-0432.CCR-11-0534
Published: 30 November 2011
View articletitled, Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
Open the PDF for Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma in another window
Journal Articles

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

John M. Kirkwood, Paul Lorigan, Peter Hersey, Axel Hauschild, Caroline Robert, David McDermott, Margaret A. Marshall, Jesus Gomez-Navarro, Jane Q. Liang, Cecile A. Bulanhagui
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (3): 1042–1048.
https://doi.org/10.1158/1078-0432.CCR-09-2033
Published: 01 February 2010
View articletitled, Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
Open the PDF for Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma in another window
Journal Articles

Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer

Michael Atkins, Meredith Regan, David McDermott, James Mier, Eric Stanbridge, Amanda Youmans, Philip Febbo, Melissa Upton, Mirna Lechpammer, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (10): 3714–3721.
https://doi.org/10.1158/1078-0432.CCR-04-2019
Published: 16 May 2005
View articletitled, Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Open the PDF for Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer in another window
Journal Articles

Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma

Michael B. Atkins, Meredith Regan, David McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6342S–6346S.
https://doi.org/10.1158/1078-0432.CCR-040029
Published: 15 September 2004
View articletitled, Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma
Open the PDF for Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma in another window
Journal Articles

Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses

David Avigan, Baldev Vasir, Jianlin Gong, Virginia Borges, Zekui Wu, Lynne Uhl, Michael Atkins, James Mier, David McDermott, Therese Smith, Nancy Giallambardo, Carolyn Stone, Kim Schadt, Jennifer Dolgoff, Jean-Claude Tetreault, Marisa Villarroel, Donald Kufe
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4699–4708.
https://doi.org/10.1158/1078-0432.CCR-04-0347
Published: 21 July 2004
View articletitled, Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses
Open the PDF for Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses in another window